SCHEDULE: CDT Equity Inc. Ownership Update: Regan Group Boosts Stake

An amendment to a Schedule 13D filing reveals updated beneficial ownership details for CDT Equity Inc. by Corvus Capital Ltd., Manoira Corporation, and Andrew Regan.

Summary

• This filing is an amendment (Amendment No. 7) to a Schedule 13D, reporting changes in beneficial ownership of CDT Equity Inc. common stock.
• The reporting persons are Corvus Capital Ltd. (Cayman Islands), Manoira Corporation (Delaware), and Dr. Andrew Regan (UK citizen).
• Dr. Andrew Regan is the CEO and sole shareholder of Corvus Capital, which owns 87% of Manoira Corporation.
• As of October 26, 2026, the total beneficial ownership for Dr. Andrew Regan is 2,064,698 shares, representing 22.1% of the outstanding shares.
• Corvus Capital Ltd. beneficially owns 1,565,080 shares (16.8%), and Manoira Corporation directly holds 1,347,619 shares (14.5%).
• The filing notes two reverse stock splits by the Issuer: a 1-for-10 split on July 20, 2026, and a 1-for-25 split on September 28, 2026.
• Manoira entered into an Evaluation Agreement with CDT Equity Inc. on October 22, 2026, to evaluate clinical stage compounds for animal health applications, receiving $195,000 and 1,347,616 shares of Common Stock.
• Dr. Regan received 499,616 shares of Common Stock on October 23, 2026, as a conversion of $65,000 of his severance payment.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, primarily due to the nature of a Schedule 13D amendment which often indicates shifts in beneficial ownership or strategic intentions rather than positive operational news.

Positives

• Manoira Corporation has entered into an Evaluation Agreement with CDT Equity Inc. to explore animal health applications for clinical stage compounds.
• Dr. Andrew Regan's beneficial ownership has increased to 22.1% of the outstanding shares, indicating continued strategic interest.
• The company has completed two reverse stock splits, which may be aimed at improving share price perception or meeting exchange listing requirements.

Negatives

• The filing is an amendment to a Schedule 13D, which typically signifies changes in control or significant stake acquisitions, often viewed with caution by the market.
• The reporting persons acquired shares through a fee for an evaluation agreement and conversion of severance pay, rather than direct open market purchases, which could be interpreted differently.

Risks

• The reporting persons reserve the right to reconsider their investment and may formulate future plans concerning the Issuer, including potential changes in control or strategic direction.
• The nature of an Evaluation Agreement suggests that the success of the animal health application exploration is not guaranteed and could impact future relationships or value.

Future Outlook

The reporting persons intend to review their investment in CDT Equity Inc. and may engage in discussions regarding the Issuer's management, operations, and strategic plans. They reserve the right to formulate future plans or proposals concerning the Issuer.

Management Comments

• Dr. Regan's principal occupation is acting as the Chief Executive Officer of Corvus Capital, an investment vehicle, and the Chief Executive Officer of the Issuer.
• The reporting persons acquired the shares of Common Stock for investment purposes.
• Each Reporting Person reserves the right, at any time and from time to time, to review or reconsider its or his position and/or change its or his purpose and/or formulate plans or proposals with respect thereto.

Industry Context

StockSavvy.ai notes that the involvement of entities like Corvus Capital and individuals like Dr. Andrew Regan in Schedule 13D filings often signals active investment or potential strategic shifts within the biotechnology or pharmaceutical sectors, especially when related to compound evaluations.

Management Changes

Related Party Transactions

• Manoira Corporation, of which Corvus Capital Ltd. owns 87% and Dr. Andrew Regan is the sole shareholder of Corvus, entered into an Evaluation Agreement with CDT Equity Inc.
• Dr. Andrew Regan received shares of Common Stock upon conversion of a portion of his severance payment from CDT Equity Inc.

Stakeholder Impact

• Shareholders: The increased beneficial ownership by Dr. Regan and his associated entities may signal a more concentrated stake, potentially influencing future strategic decisions or control.
• Employees: Changes in management or strategic direction stemming from increased stakeholder influence could impact employee roles and company operations.
• Creditors: The company's financial stability and strategic direction, influenced by major shareholders, are relevant to creditors.

Next Steps

• The reporting persons will continue to review their investment in CDT Equity Inc.
• Discussions may occur with the Issuer's management, other stockholders, and relevant parties regarding the company's affairs.
• Future plans or proposals concerning the Issuer may be formulated based on reviews and discussions.

Key Dates

Recommendation

The filing is an amendment to a Schedule 13D, indicating changes in beneficial ownership rather than operational performance. While the increased stake by Dr. Regan and the Evaluation Agreement are noteworthy, they do not provide sufficient positive or negative performance indicators to warrant a buy or sell recommendation. A 'hold' stance allows for further observation of the strategic implications.

Keywords

CDT Equity Inc., Schedule 13D, Beneficial Ownership, Corvus Capital Ltd., Manoira Corporation, Andrew Regan, Reverse Stock Split, Evaluation Agreement